GC Cell’s CAR-NK Therapy GCC2005 Approved for Compassionate Use in Refractory T-Cell Lymphoma at SNUH, South Korea

September 20, 2026

Korea Biomedical Review South Korea

Overview

GC Cell’s CAR-NK cell therapy, GCC2005, has received approval for compassionate use in patients with refractory T-cell lymphoma at Seoul National University Hospital (SNUH) in South Korea. This approval follows the completion of the Phase 1a dosing in Korea and precedes the initiation of Phase 1b, offering a critical new treatment option for patients who have failed standard anti-cancer therapies. The move underscores the potential of allogeneic CAR-NK platforms to address high unmet medical needs with a potentially improved safety profile compared to CAR-T therapies.

In Depth

Key Findings

GC Cell’s CAR-NK cell therapy, GCC2005, has been granted compassionate use approval at Seoul National University Hospital (SNUH) for patients suffering from refractory T-cell lymphoma. This landmark decision provides a crucial lifeline for individuals who have exhausted conventional anti-cancer treatments and highlights the growing confidence in novel cellular immunotherapies.

Technical and Clinical Details

GCC2005 is an allogeneic CAR-NK cell therapy designed to target specific tumor-associated antigens, enabling genetically modified natural killer (NK) cells to precisely and powerfully eliminate cancer cells. Unlike autologous CAR-T therapies, which require patient-specific cell collection and manufacturing, CAR-NK cells can be derived from healthy donors, allowing for off-the-shelf availability. GC Cell has successfully completed the Phase 1a portion of the trial in South Korea, with preliminary data suggesting a favorable safety profile and early indicators of efficacy. The compassionate use approval mechanism allows critically ill patients, for whom no other treatment options exist, to access promising experimental therapies outside of a formal clinical trial, reflecting a regulatory acknowledgment of GCC2005’s therapeutic potential for a high-unmet-need population like T-cell lymphoma patients.

Background and Industry Context

T-cell lymphoma is an aggressive cancer with a poor prognosis and limited effective treatment options, driving an urgent need for innovative therapeutic strategies. CAR-NK cell therapies are gaining significant traction in the oncology landscape due to their potential advantages over CAR-T cells, including a lower risk of severe adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as simplified manufacturing processes. This compassionate use approval marks a significant milestone for GC Cell, advancing their pipeline and contributing to the broader trend of expanding access to cutting-edge regenerative medicines in South Korea. The global cellular therapy market is rapidly evolving, with a focus on enhancing accessibility and safety while broadening the scope of treatable diseases.

Strategic Significance and Outlook

GC Cell is actively preparing to launch its Phase 1b clinical trial, which will further evaluate the safety and efficacy of GCC2005 in a larger patient cohort. Data collected from this compassionate use will offer valuable insights that could inform future clinical development strategies and regulatory interactions. The approval also strengthens GC Cell’s position in the competitive CAR-NK space, where companies worldwide are striving to develop effective, readily available cell therapies. Success in the upcoming trials could position GCC2005 as a transformative treatment for refractory T-cell lymphoma, potentially shifting the treatment paradigm for this challenging disease.

Source: https://www.koreabiomed.com/news/articleView.html?idxno=33234

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.